1
|
Abstract
The enhanced understanding of immunology experienced over the last 5 decades afforded through the tools of molecular biology has recently translated into cancer immunotherapy becoming one of the most exciting and rapidly expanding fields. Human cancer immunotherapy is now recognized as one of the pillars of treatment alongside surgery, radiation, and chemotherapy. The field of veterinary cancer immunotherapy has also rapidly advanced in the last decade with a handful of commercially available products and a plethora of investigational cancer immunotherapies, which will hopefully expand our veterinary oncology treatment toolkit over time.
Collapse
Affiliation(s)
- Philip J Bergman
- Clinical Studies, VCA; Katonah Bedford Veterinary Center, Bedford Hills, NY, USA; Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
| |
Collapse
|
2
|
Martini F, Rostaher A, Favrot C, Fischer NM. Open trial of recombinant Der f 2 pullulan-conjugated immunotherapy in cats. Vet Dermatol 2024; 35:175-183. [PMID: 38073305 DOI: 10.1111/vde.13217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 08/26/2023] [Accepted: 11/20/2023] [Indexed: 03/05/2024]
Abstract
BACKGROUND Allermmune HDM (Zenoaq) is a recombinant Dermatophagoides farinae 2 (Der f 2) pullulan-based immunotherapy vaccine whose efficacy on house dust mite allergic dogs has been demonstrated. There is no published information on its use in cats. OBJECTIVES The objective of the study was to evaluate the safety and short-term effects of Allermmune HDM in Dermatophagoides farinae (Df)-sensitised cats. MATERIALS AND METHODS Eleven cats diagnosed with atopic skin syndrome received Allermmune weekly for six weeks then monthly for three months (total duration 18 weeks). On Weeks 0, 6 and 18 clinical lesions were assessed by the Feline Dermatitis Extent and Severity Index (FEDESI); owners assessed pruritus with a 10-cm Visual Analog Scale (pVAS). Concurrent medication use was recorded. The allergen-specific immunoglobulin (Ig)E were measured before study inclusion with a commercial serological assay. RESULTS There were no evident adverse effects. FEDESI and pVAS improved significantly after six weeks (p = 0.001 and p = 0.01, respectively). The pretreatment Df-specific IgE levels were significantly higher in the cats with improved clinical scores than in the cats with no clinical score change (p = 0.009). CONCLUSIONS AND CLINICAL RELEVANCE Allermmune HDM may be safe in cats and has the potential to alleviate signs of atopic skin syndrome. Allergen-specific IgE levels may represent an efficacy marker. Controlled studies of longer duration and larger sample size are worth pursuing.
Collapse
Affiliation(s)
- Franco Martini
- Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Ana Rostaher
- Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Claude Favrot
- Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Nina M Fischer
- Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| |
Collapse
|
3
|
Moore A, Burrows AK, Rosenkrantz WS, Ghubash RM, Hosgood G. Modified rush venom immunotherapy in dogs with Hymenoptera hypersensitivity. Vet Dermatol 2023; 34:532-542. [PMID: 37395162 DOI: 10.1111/vde.13189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 04/22/2023] [Accepted: 06/18/2023] [Indexed: 07/04/2023]
Abstract
BACKGROUND Hymenoptera envenomation occurs frequently in people and dogs and can trigger anaphylaxis. Venom immunotherapy (VIT) is the only preventive treatment for Hymenoptera hypersensitivity and is indicated for people with severe adverse reactions to insect stings. Rush VIT is an accelerated VIT protocol in people. This has not been reported in dogs. OBJECTIVES The objective of the study was to evaluate the safety of modified rush VIT. ANIMALS Twenty client-owned dogs with Hymenoptera hypersensitivity based on a history of adverse reactions to Hymenoptera envenomation and a positive intradermal test to honey bee and/or paper wasp venom. MATERIALS AND METHODS Dogs received incremental doses of venom via subcutaneous injection one day per week for three consecutive weeks until the maintenance dose was achieved. Vital signs were recorded every 30 min prior to venom administration. Adverse reactions were categorised as localised or grade I-IV systemic reactions. RESULTS Nineteen of 20 dogs (95%) completed rush VIT. One dog experienced a grade III systemic adverse reaction and was withdrawn from the study. No adverse reactions occurred in 10 of 20 dogs (50%). Localised and grade I-II systemic reactions occurred in nine of 20 dogs (45%), including nausea (n = 5), injection site pruritus (n = 3) and diarrhoea and lethargy (n = 1). CONCLUSIONS AND CLINICAL RELEVANCE Modified rush VIT in dogs was well-tolerated and should be considered for dogs with Hymenoptera hypersensitivity. Larger studies are needed to evaluate the efficacy of VIT in dogs for preventing hypersensitivity reactions to insect stings.
Collapse
Affiliation(s)
- Alexandra Moore
- Animal Dermatology Clinic Perth, The Animal Hospital Murdoch University, Murdoch, Western Australia, Australia
| | - Amanda K Burrows
- Animal Dermatology Clinic Perth, The Animal Hospital Murdoch University, Murdoch, Western Australia, Australia
| | | | | | - Giselle Hosgood
- College of Veterinary Medicine, The Animal Hospital Murdoch University, Murdoch, Western Australia, Australia
| |
Collapse
|
4
|
Weitzer T, Mueller R. The safety of rush immunotherapy in the management of canine atopic dermatitis-230 cases. Vet Dermatol 2023; 34:385-392. [PMID: 37157908 DOI: 10.1111/vde.13170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 03/08/2023] [Accepted: 03/09/2023] [Indexed: 05/10/2023]
Abstract
BACKGROUND The duration of the induction phase of allergen-specific immunotherapy conventionally is a period of several weeks, during which the volume of an allergen solution, administered by injection, is gradually increased until the maintenance dose is reached. In rush immunotherapy (RIT), the induction period is abbreviated to achieve a faster improvement in clinical signs of atopic dermatitis (AD) compared to conventional immunotherapy. OBJECTIVE The aim of this retrospective study was to evaluate the safety of RIT in 230 dogs with AD and report any adverse effects (AE). ANIMALS Two hundred thirty client-owned dogs. MATERIALS AND METHODS Medical records of dogs receiving RIT between 2012 and 2021 were analysed and observed AE were investigated. All dogs underwent RIT following a protocol of subcutaneous allergen extract injections, given hourly with an incrementally increasing volume from 0.1 to 1.0 mL. RESULTS Adverse effects were documented in 6 of 230 (2.6%) dogs. Five of these dogs (2.2%) showed mild gastrointestinal signs (1 of 5 vomiting, 4 of 5 diarrhoea) and one patient an increase in body temperature by 1.5°C. These occurred at different stages of the RIT protocol. All AE were graded as mild and self-limiting. CONCLUSIONS AND CLINICAL RELEVANCE Based on these data, supervised RIT in dogs appears to be a safe procedure to achieve the maintenance dose of allergen immunotherapy earlier with infrequent and mild AE.
Collapse
Affiliation(s)
- Tamara Weitzer
- Center for Clinical Veterinary Medicine, LMU Munich, Munich, Germany
| | - Ralf Mueller
- Center for Clinical Veterinary Medicine, LMU Munich, Munich, Germany
| |
Collapse
|
5
|
Ammons DT, MacDonald CR, Chow L, Repasky EA, Dow S. Chronic adrenergic stress and generation of myeloid-derived suppressor cells: Implications for cancer immunotherapy in dogs. Vet Comp Oncol 2023; 21:159-165. [PMID: 36876492 DOI: 10.1111/vco.12891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Revised: 02/28/2023] [Accepted: 03/01/2023] [Indexed: 03/07/2023]
Abstract
Recent studies have highlighted a key role played by the sympathetic nervous system (SNS) and adrenergic stress in mediating immune suppression associated with chronic inflammation in cancer and other diseases. The connection between chronic SNS activation, adrenergic stress and immune suppression is linked in part to the ability of catecholamines to stimulate the bone marrow release and differentiation of myeloid-derived suppressor cells (MDSC). Rodent model studies have revealed an important role for β-adrenergic receptor signalling in suppression of cancer immunity in mice subjected to chronic stresses, including thermal stress. Importantly, therapeutic blockade of beta-adrenergic responses by drugs such as propranolol can partially reverse the generation and differentiation of MDSC, and partly restore tumour immunity. Clinical trials in both humans and dogs with cancer have demonstrated that propranolol blockade can improve responses to radiation therapy, cancer vaccines and immune checkpoint inhibitors. Thus, the SNS stress response has become an important new target to relieve immune suppression in cancer and other chronic inflammatory conditions.
Collapse
Affiliation(s)
- Dylan T Ammons
- Flint Animal Cancer Center, Fort Collins, Colorado, USA
- Department of Microbiology, Immunology, and Pathology, Fort Collins, Colorado, USA
| | - Cameron R MacDonald
- Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
| | - Lyndah Chow
- Flint Animal Cancer Center, Fort Collins, Colorado, USA
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| | - Elizabeth A Repasky
- Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
| | - Steven Dow
- Flint Animal Cancer Center, Fort Collins, Colorado, USA
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| |
Collapse
|
6
|
Proksch SF, Matthysen CP, Jardine JE, Wyatt KM, Finlay JR, Nelson DJ. Developing a translational murine-to-canine pathway for an IL-2/agonist anti-CD40 antibody cancer immunotherapy. Vet Comp Oncol 2022; 20:602-612. [PMID: 35315197 PMCID: PMC9540797 DOI: 10.1111/vco.12813] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Revised: 03/14/2022] [Accepted: 03/14/2022] [Indexed: 11/29/2022]
Abstract
Human and canine sarcomas are difficult to treat soft tissue malignancies with an urgent need for new improved therapeutic options. Local recurrence rates for humans are between 10%-30%, and 30%-40% develop metastases. Outcomes for dogs with sarcoma vary with grade but can be similar. Pet dogs share the human environment and represent human cancer with genetic variation in hosts and tumours. We asked if our murine studies using genetically identical mice and cloned tumour cells were translatable to larger, genetically diverse domestic dogs with naturally occurring tumours, to (i) develop a canine cancer therapeutic, and (ii) to use as a translational pathway to humans. Our murine studies showed that intra-tumoral delivery of interleukin-2 (IL-2) plus an agonist anti-CD40 antibody (Ab) induces long-term curative responses ranging from 30% to 100%, depending on tumour type. We developed an agonist anti-canine-CD40 Ab and conducted a phase I dose finding/toxicology 3 + 3 clinical trial in dogs (n = 27) with soft tissue sarcomas on account of suitability for intratumoral injection and straightforward monitoring. Dogs were treated with IL-2 plus anti-CD40 antibody for 2 weeks. Three dose levels induced tumour regression with minimal side effects, measured by monitoring, haematological and biochemical assays. Importantly, our mouse and canine studies provide encouraging fundamental proof-of-concept data upon which we can develop veterinary and human immunotherapeutic strategies.
Collapse
Affiliation(s)
- Stephen Francis Proksch
- Curtin Medical SchoolCurtin UniversityBentleyWestern AustraliaAustralia
- CHIRI BiosciencesCurtin UniversityBentleyWestern AustraliaAustralia
- Selvax Pty LtdWest PerthWestern AustraliaAustralia
| | - Clinton Petrus Matthysen
- Curtin Medical SchoolCurtin UniversityBentleyWestern AustraliaAustralia
- CHIRI BiosciencesCurtin UniversityBentleyWestern AustraliaAustralia
| | | | - Ken Mark Wyatt
- Perth Veterinary Specialists (PVS)Osborne ParkWestern AustraliaAustralia
| | | | - Delia Jane Nelson
- Curtin Medical SchoolCurtin UniversityBentleyWestern AustraliaAustralia
- CHIRI BiosciencesCurtin UniversityBentleyWestern AustraliaAustralia
| |
Collapse
|
7
|
Arsuaga-Zorrilla CB, Grooters AM, Pucheu-Haston CM. Quantitation of anti-Pythium insidiosum antibodies before and after administration of an immunotherapeutic product to healthy dogs. Am J Vet Res 2018; 79:1160-1165. [PMID: 30372150 DOI: 10.2460/ajvr.79.11.1160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To evaluate the effect of an immunotherapeutic product on concentrations of anti-Pythium insidiosum antibodies in dogs. ANIMALS 7 healthy hound-crossbreds. PROCEDURES Antibody concentrations were evaluated before (day 0) and after administration of the immunotherapeutic product. The immunotherapeutic product was administered on days 0, 7, and 21. Serum was obtained on days 0, 7, 14, 21, 28, 35, 42, 49, and 56. Anti-P insidiosum antibody concentrations were measured and reported as the percentage positivity relative to results for a strongly positive control serum. RESULTS Mean ± SD percentage positivity before administration of the immunotherapeutic product was 7.45 ± 3.02%. There was no significant change in anti-P insidiosum antibody concentrations after administration of the product, with percentage positivity values in all dogs remaining within the range expected for healthy dogs (3% to 15%). CONCLUSIONS AND CLINICAL RELEVANCE Administration of the immunotherapeutic product to healthy dogs in accordance with the manufacturer's suggested protocol did not induce a significant change in anti-P insidiosum antibody concentrations. These results suggested that administration of the immunotherapeutic product may not interfere with postadministration serologic monitoring. However, further investigations will be required to determine whether there is a similar effect in naturally infected dogs.
Collapse
|
8
|
Hernández-Granados AJ, Franco-Molina MA, Coronado-Cerda EE, Zapata-Benavides P, Gamboa EM, Ramos-Zayas Y, Santana-Krímskaya SE, Rodríguez-Padilla C. Immunogenic potential of three transmissible venereal tumor cell lysates to prime canine-dendritic cells for cancer immunotherapy. Res Vet Sci 2018; 121:23-30. [PMID: 30316013 DOI: 10.1016/j.rvsc.2018.10.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 10/01/2018] [Accepted: 10/02/2018] [Indexed: 11/18/2022]
Abstract
Whole tumor cell lysates consist of a mixture of tumor antigens and danger associated molecular patterns (DAMPs) that can be used for dendritic cell maturation and consequently for the activation of a polyclonal T cell-specific tumor response. We evaluated the in vitro efficacy of three different preparations of canine transmissible venereal tumor (TVT) cell lysates: hypochlorous acid-whole tumor cell lysates (HOCl-L), heat shock-whole tumor cell lysates (HS-L), and freeze-thaw cycles-whole tumor cell lysates (FT-L) for the maturation of canine-derived dendritic cells. Our results showed calreticulin, HSP70, and HSP90 release in the three tumor lysates preparations (HOCl-L, HS-L, and FT-L); however, HMGB1 was detected only in HOCl-L and FT-L. Additionally, the uptake by HOCl-L pulsed dendritic cell (DC) increased compared to HS-L and FT-L pulsed DC; and dendritic cell maturation was confirmed by the appropriate cell surface markers (CD11c, CD80, CD83, and MHCII). Furthermore, dendritic cells pulsed with HOCl-L, HS-L or FT-L were cultured with canine lymphocytes. There was an increase of Th1-type cytokines (IL-12, TNF-α, and IFN-γ), in all the tumor cell lysates co-cultures, this correlates with T lymphocyte activation and cytotoxic response. Our data confirm that TVT cell lysates can induce functional canine-DC and that HOCl-L is the most effective one. This preparation of TVT cell lysates with HOCl is an attractive approach that allows the recognition of neoantigens as potential tumor targets and DC priming and therefore could be used for cancer immunotherapy against TVT.
Collapse
Affiliation(s)
- Alex Jesús Hernández-Granados
- Laboratorio de Inmunologia y Virologia, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León (UANL), PO BOX 46, "F" Zip Code 66455, San Nicolás de los Garza, N. L., Mexico
| | - Moisés Armides Franco-Molina
- Laboratorio de Inmunologia y Virologia, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León (UANL), PO BOX 46, "F" Zip Code 66455, San Nicolás de los Garza, N. L., Mexico.
| | - Erika Evangelina Coronado-Cerda
- Laboratorio de Inmunologia y Virologia, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León (UANL), PO BOX 46, "F" Zip Code 66455, San Nicolás de los Garza, N. L., Mexico
| | - Pablo Zapata-Benavides
- Laboratorio de Inmunologia y Virologia, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León (UANL), PO BOX 46, "F" Zip Code 66455, San Nicolás de los Garza, N. L., Mexico
| | - Edgar Mendoza Gamboa
- Laboratorio de Inmunologia y Virologia, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León (UANL), PO BOX 46, "F" Zip Code 66455, San Nicolás de los Garza, N. L., Mexico
| | - Yareellys Ramos-Zayas
- Laboratorio de Inmunologia y Virologia, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León (UANL), PO BOX 46, "F" Zip Code 66455, San Nicolás de los Garza, N. L., Mexico
| | - Silvia Elena Santana-Krímskaya
- Laboratorio de Inmunologia y Virologia, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León (UANL), PO BOX 46, "F" Zip Code 66455, San Nicolás de los Garza, N. L., Mexico
| | - Cristina Rodríguez-Padilla
- Laboratorio de Inmunologia y Virologia, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León (UANL), PO BOX 46, "F" Zip Code 66455, San Nicolás de los Garza, N. L., Mexico
| |
Collapse
|
9
|
Gyles C. Cancer immunotherapy - a promising approach. Can Vet J 2018; 59:825-827. [PMID: 30104771 PMCID: PMC6042608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Affiliation(s)
- Carlton Gyles
- Opinions expressed in this column are those of the Editor
| |
Collapse
|
10
|
Soria I, Alvarez J, Manzano AI, López-Relaño J, Cases B, Mas-Fontao A, Cañada FJ, Fernández-Caldas E, Casanovas M, Jiménez-Barbero J, Palomares O, Viñals-Flórez LM, Subiza JL. Mite allergoids coupled to nonoxidized mannan from Saccharomyces cerevisae efficiently target canine dendritic cells for novel allergy immunotherapy in veterinary medicine. Vet Immunol Immunopathol 2017; 190:65-72. [PMID: 28778325 DOI: 10.1016/j.vetimm.2017.07.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Revised: 07/07/2017] [Accepted: 07/10/2017] [Indexed: 12/29/2022]
Abstract
We have recently reported that grass pollen allergoids conjugated with nonoxidized mannan of Saccharomyces cerevisae using glutaraldehyde results in a novel hypoallergenic mannan-allergen complex with improved properties for allergen vaccination. Using this approach, human dendritic cells show a better allergen uptake and cytokine profile production (higher IL-10/IL-4 ratio) for therapeutic purposes. Here we aim to address whether a similar approach can be extended to dogs using canine dendritic cells. Six healthy Spanish Greyhound dogs were used as blood donors to obtain canine dendritic cells (DC) derived from peripheral blood monocytes. Allergens from Dermatophagoides farinae mite were polymerized and conjugated with nonoxidized mannan. Nuclear magnetic resonance (NMR), gel electrophoresis (SDS-PAGE), immunoblotting and IgE-ELISA inhibition studies were conducted to evaluate the main characteristics of the allergoid obtained. Mannan-allergen conjugate and controls were assayed in vitro for canine DC uptake and production of IL-4 and IL-10. The results indicate that the conjugation of D. farinae allergens with nonoxidized mannan was feasible using glutaraldehyde. The resulting product was a polymerized structure showing a high molecular weight as detected by NMR and SDS-PAGE analysis. The mannan-allergen conjugate was hypoallergenic with a reduced reactivity with specific dog IgE. An increase in both allergen uptake and IL-10/IL-4 ratio was obtained when canine DCs were incubated with the mannan-allergen conjugate, as compared with the control allergen preparations (unmodified D. farinae allergens and oxidized mannan-allergen conjugate). We conclude that hypoallergenic D. farinae allergens coupled to nonoxidized mannan is a novel allergen preparation suitable for canine allergy immunotherapy targeting dendritic cells.
Collapse
Affiliation(s)
| | | | - Ana I Manzano
- Inmunotek S.L., Alcalá de Henares, Spain; Centro de Investigaciones Biológicas, Madrid, Spain
| | - Juan López-Relaño
- Inmunotek S.L., Alcalá de Henares, Spain; Experimental Unit, Hospital Clínico San Carlos, Madrid, Spain
| | | | | | | | - Enrique Fernández-Caldas
- Inmunotek S.L., Alcalá de Henares, Spain; Division of Allergy and Immunology, University of South Florida, College of Medicine, Tampa, USA
| | | | - Jesús Jiménez-Barbero
- Centro de Investigaciones Biológicas, Madrid, Spain; CIC bioGUNE, Parque Tecnológico de Bizkaia, Bilbao, Spain
| | - Oscar Palomares
- Dpto. Bioquímica y Biología Molecular, Universidad Complutense, Madrid, Spain
| | | | | |
Collapse
|
11
|
Kolotilin I, Topp E, Cox E, Devriendt B, Conrad U, Joensuu J, Stöger E, Warzecha H, McAllister T, Potter A, McLean MD, Hall JC, Menassa R. Plant-based solutions for veterinary immunotherapeutics and prophylactics. Vet Res 2014; 45:117. [PMID: 25559098 PMCID: PMC4280687 DOI: 10.1186/s13567-014-0117-4] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Accepted: 10/30/2014] [Indexed: 12/19/2022] Open
Abstract
An alarming increase in emergence of antibiotic resistance among pathogens worldwide has become a serious threat to our ability to treat infectious diseases according to the World Health Organization. Extensive use of antibiotics by livestock producers promotes the spread of new resistant strains, some of zoonotic concern, which increases food-borne illness in humans and causes significant economic burden on healthcare systems. Furthermore, consumer preferences for meat/poultry/fish produced without the use of antibiotics shape today's market demand. So, it is viewed as inevitable by the One Health Initiative that humans need to reduce the use of antibiotics and turn to alternative, improved means to control disease: vaccination and prophylactics. Besides the intense research focused on novel therapeutic molecules, both these strategies rely heavily on the availability of cost-effective, efficient and scalable production platforms which will allow large-volume manufacturing for vaccines, antibodies and other biopharmaceuticals. Within this context, plant-based platforms for production of recombinant therapeutic proteins offer significant advantages over conventional expression systems, including lack of animal pathogens, low production costs, fast turnaround and response times and rapid, nearly-unlimited scalability. Also, because dried leaves and seeds can be stored at room temperature for lengthy periods without loss of recombinant proteins, plant expression systems have the potential to offer lucrative benefits from the development of edible vaccines and prophylactics, as these would not require "cold chain" storage and transportation, and could be administered in mass volumes with minimal processing. Several biotechnology companies currently have developed and adopted plant-based platforms for commercial production of recombinant protein therapeutics. In this manuscript, we outline the challenges in the process of livestock immunization as well as the current plant biotechnology developments aimed to address these challenges.
Collapse
Affiliation(s)
- Igor Kolotilin
- />Department of Biology, University of Western Ontario, 1151 Richmond St, London, ON Canada
| | - Ed Topp
- />AAFC, Southern Crop Protection and Food Research Centre, 1391 Sandford St, London, ON Canada
| | - Eric Cox
- />Laboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
| | - Bert Devriendt
- />Laboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
| | - Udo Conrad
- />Leibniz Institute of Plant Genetics and Crop Plant Research, Gatersleben, Germany
| | - Jussi Joensuu
- />VTT Technical Research Centre of Finland, Espoo, Finland
| | - Eva Stöger
- />Department for Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Heribert Warzecha
- />Technische Universität Darmstadt, FB Biologie, Schnittspahnstr. 5, D-64287 Darmstadt, Germany
| | - Tim McAllister
- />AAFC, Lethbridge Research Centre, 5403, 1 Avenue South, Lethbridge, Alberta Canada
| | - Andrew Potter
- />Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, 120 Veterinary Road, Saskatoon, Saskatchewan Canada
- />Department of Veterinary Microbiology, University of Saskatchewan, 120 Veterinary Road, Saskatoon, Saskatchewan Canada
| | - Michael D McLean
- />PlantForm Corp., c/o Room 2218, E.C. Bovey Bldg, University of Guelph, Guelph, Ontario N1G 2 W1 Canada
| | - J Christopher Hall
- />School of Environmental Sciences, University of Guelph, 50 Stone Road East, Guelph, Ontario N1G 2 W1 Canada
| | - Rima Menassa
- />Department of Biology, University of Western Ontario, 1151 Richmond St, London, ON Canada
- />AAFC, Southern Crop Protection and Food Research Centre, 1391 Sandford St, London, ON Canada
| |
Collapse
|
12
|
Hobi S, Mueller RS. Efficacy and safety of rush immunotherapy with alum-precipitated allergens in canine atopic dermatitis. Tierarztl Prax Ausg K Kleintiere Heimtiere 2014; 42:167-173. [PMID: 24920143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/02/2013] [Accepted: 02/24/2014] [Indexed: 06/03/2023]
Abstract
OBJECTIVES Canine atopic dermatitis is a very common disease in small animal practice. Its only specific treatment is allergen immunotherapy. In rush-immunotherapy (RIT) increasing doses of allergen extract are injected subcutaneously in short intervals. Maintenance doses are achieved within one day compared to weeks or months with conventional immunotherapy. The aim of this study was to evaluate the safety and efficacy of RIT with alum-precipitated allergens. MATERIALS AND METHODS A series of 20 dogs with atopic dermatitis underwent RIT with alum-precipitated allergens. Pruritus and medications at the start of the immunotherapy and 12 months afterwards were compared and adverse effects were recorded. RESULTS Significant improvement in pruritus (p = 0.0001) and medication scores (p = 0.0004) was noted after approximately 12 months of treatment. The observed clinical response was good to excellent in 70% of the dogs, consistent with other published reports. One dog vomited once during the induction day, with no other clinical problems and completion of the normal protocol. The other 19 dogs showed no adverse effects at all during or after RIT. CONCLUSION AND CLINICAL RELEVANCE RIT with alum-precipitated allergens seems to be a safe and efficacious method to treat dogs with atopic dermatitis.
Collapse
Affiliation(s)
- S Hobi
- Stefan Hobi, Medizinische Kleintierklinik, Ludwig-Maximilians-Universität, Veterinärstraße 13, 80539 München, Germany,
| | | |
Collapse
|
13
|
Klier J, Fuchs S, May A, Schillinger U, Plank C, Winter G, Coester C, Gehlen H. A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses. Pharm Res 2012; 29:1650-7. [PMID: 22302522 DOI: 10.1007/s11095-012-0686-8] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2011] [Accepted: 01/17/2012] [Indexed: 12/28/2022]
Abstract
PURPOSE In the recent years, nanotechnology has boosted the development of potential drug delivery systems and material engineering on nanoscale basis in order to increase drug specificity and reduce side effects. A potential delivery system for immunostimulating agents such as cytosine-phosphate-guanine-oligodeoxynucleotides (CpG-ODN) needs to be developed to maximize the efficacy of immunotherapy against hypersensitivity. In this study, an aerosol formulation of biodegradable, biocompatible and nontoxic gelatin nanoparticle-bound CpG-ODN 2216 was used to treat equine recurrent airway obstruction in a clinical study. METHODS Bronchoalveolar lavage fluid was obtained from healthy and allergic horses to quantify Th1/Th2 cytokine levels before and after inhalation regimen. Full clinical examinations were performed to evaluate the therapeutic potential of this nebulized gelatin nanoparticle-based CpG formulation. RESULTS Most remarkable was that regulatory anti-inflammatory and anti-allergic cytokine IL-10 expression was significantly triggered by five consecutive inhalations. Thorough assessment of clinical parameters following nanoparticle treatment indicated a partial remission of the allergic condition. CONCLUSION Thus this study, for the first time, showed effectiveness of colloidal nanocarrier-mediated immunotherapy in food-producing animals with potential future applicability to other species including humans.
Collapse
Affiliation(s)
- John Klier
- Department of Veterinary Medicine, Equine Clinic, Ludwig Maximilians University, Munich, Germany
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Granger N, Smith PM, Jeffery ND. Clinical findings and treatment of non-infectious meningoencephalomyelitis in dogs: a systematic review of 457 published cases from 1962 to 2008. Vet J 2010; 184:290-7. [PMID: 19410487 DOI: 10.1016/j.tvjl.2009.03.031] [Citation(s) in RCA: 117] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2008] [Revised: 03/25/2009] [Accepted: 03/27/2009] [Indexed: 11/22/2022]
Abstract
Non-infectious meningoencephalomyelitis (NIME) presents clinicians with diagnostic problems because specific diagnosis requires histopathological examination of central nervous system (CNS) tissue. In the absence of a precise diagnosis, clinicians refer instead to 'meningoencephalomyelitis of unknown origin' (MUO). This article compares published data on histopathologically diagnosed disease (granulomatous meningoencephalomyelitis and necrotising encephalitis) with information available on the clinically-defined category of MUO. Small, middle-aged female dogs are most commonly affected by all types of NIME, but there is considerable overlap in diagnostic parameters of these diseases. Future clinical trials must aim to compare prospectively two or more randomly allocated treatments and to include pre-trial power calculations. This article provides the necessary background information to permit rational patient selection on clinical presentation alone, rather than requiring CNS biopsy, thus maximising patient recruitment whilst minimising heterogeneity.
Collapse
Affiliation(s)
- Nicolas Granger
- Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, CB3 0ES, UK
| | | | | |
Collapse
|
15
|
Mealey RH, Littke MH, Leib SR, Davis WC, McGuire TC. Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy. Vet Immunol Immunopathol 2008; 121:8-22. [PMID: 17727961 PMCID: PMC2967287 DOI: 10.1016/j.vetimm.2007.07.011] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2007] [Revised: 06/24/2007] [Accepted: 07/11/2007] [Indexed: 01/08/2023]
Abstract
Although CTL are important for control of lentiviruses, including equine infectious anemia virus (EIAV), it is not known if CTL can limit lentiviral replication in the absence of CD4 help and neutralizing antibody. Adoptive transfer of EIAV-specific CTL clones into severe combined immunodeficient (SCID) foals could resolve this issue, but it is not known whether exogenous IL-2 administration is sufficient to support the engraftment and proliferation of CTL clones infused into immunodeficient horses. To address this question we adoptively transferred EIAV Rev-specific CTL clones into four EIAV-challenged SCID foals, concurrent with low-dose aldesleukin (180,000U/m2), a modified recombinant human IL-2 (rhuIL-2) product. The dose was calculated based on the specific activity on equine PBMC in vitro, and resulted in plasma concentrations considered sufficient to saturate high affinity IL-2 receptors in humans. Despite specific activity on equine PBMC that was equivalent to recombinant equine IL-2 and another form of rhuIL-2, aldesleukin did not support the engraftment and expansion of infused CTL clones, and control of viral load and clinical disease did not occur. It was concluded that survival of Rev-specific CTL clones infused into EIAV-challenged SCID foals was not enhanced by aldesleukin at the doses used in this study, and that in vitro specific activity did not correlate with in vivo efficacy. Successful adoptive immunotherapy with CTL clones in immunodeficient horses will likely require higher doses of rhuIL-2, co-infusion of CD4+ T lymphocytes, or administration of equine IL-2.
Collapse
Affiliation(s)
- Robert H Mealey
- Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, Washington 99164-7040, United States.
| | | | | | | | | |
Collapse
|
16
|
Dec M, Puchalski A. Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases. Pol J Vet Sci 2008; 11:175-186. [PMID: 18683548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Interferon-alpha (IFN-alpha) is well known as a clinically effective antiviral and antineoplastic therapeutic agent. It has also been shown to have immunoregulatory properties. IFN-alpha stimulates a cell-mediated innate immune response and then participates in the transition of the initial host innate response to an effective adaptive immune response. IFN-alpha is produced in small quantities in nasal secretions during viral infections, prompting many authors to suggest that low-dose oromucosal administration of IFN-alpha effectively mimics nature. Moreover, the injectable high-dose interferon therapy currently approved for various human disorders causes numerous side effects. By contrast, oromucosal administration of IFN-alpha is not associated with toxic effects. Another distinct advantage is ease of administration: the IFN can be dissolved in drinking water or administered by nebulization to the oral or nasal cavity. This review describes the current state of knowledge concerning orally administered IFN-alpha, of both human and animal origin, as a prophylactic or therapeutic agent in veterinary medicine. We present the effects of IFN-alpha in such animals as cattle, pigs, horses, cats, dogs and chickens, and attempt to explain its mechanism of action following oromucosal administration. It is hoped that this review of the medical literature on the use of IFN-alpha in animals will give practitioners a better understanding of the challenges and benefits of using this interesting cytokine in clinical practice.
Collapse
Affiliation(s)
- M Dec
- University of Life Sciences, Faculty of Veterinary Medicine, Institute of Biological Bases of Animal Diseases, Department of Veterinary Prevention, Lublin, Poland.
| | | |
Collapse
|
17
|
Breathnach RM, Fanning S, Mulcahy G, Bassett HF, Jones BR. Canine pododermatitis and idiopathic disease. Vet J 2007; 176:146-57. [PMID: 17919951 DOI: 10.1016/j.tvjl.2007.05.027] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2007] [Revised: 05/04/2007] [Accepted: 05/09/2007] [Indexed: 11/19/2022]
Abstract
Pododermatitis is a common inflammatory skin disease of dogs. As pedal lesions are reported in many canine dermatoses, a methodical series of diagnostic tests is required to establish the underlying aetiology. However, laboratory/ancillary investigations may prove unrewarding, prompting a diagnosis of idiopathic disease. Various hypotheses have been proposed to explain the pathogenesis of idiopathic pododermatitis including pedal conformation, trauma, immunosuppression, bacterial infection, furunculosis and dermal granuloma formation. Idiopathic pododermatitis accounts for 0.5% of all dermatology referrals to the authors' clinic. A sub-group within this population is characterised histopathologically by epidermal hyperplasia, hyperkeratosis, spongiosis, dermal oedema and perivascular aggregates of lymphocytes and plasma cells. The term lymphocytic-plasmacytic pododermatitis (LPP) has previously been proposed to reflect the histological appearance of such lesions. Affected dogs, although systemically well, characteristically have pruritus, erythema, swelling, pain and alopecia of the feet. Although non-responsive to antimicrobial therapy, antiparasitic agents and elimination diets, these dogs typically respond well to immunomodulatory therapy.
Collapse
Affiliation(s)
- Rory M Breathnach
- School of Agriculture, Food Science and Veterinary Medicine, University College Dublin, Dublin 4, Ireland.
| | | | | | | | | |
Collapse
|
18
|
Abstract
Feline allergen specific immunotherapy (ASIT) is considered to be a safe and effective treatment for feline atopy. ASIT is defined as the practice of administering gradually increasing quantities of an allergen extract to an allergic subject. The purpose of which is to reduce or eliminate the symptoms associated with subsequent exposures to the causative allergen. ASIT offers an effective and safe treatment option for cats. Reported success rates range for 60 to 78% in feline atopic patients. Additionally, the reported incidence of side effects in feline atopic patients undergoing ASIT is very low and mainly anecdotal.
Collapse
Affiliation(s)
- Ann M Trimmer
- Animal Dermatology Clinic, San Diego, CA 92111, USA.
| | | | | |
Collapse
|
19
|
Abstract
Infectious bursal disease (IBD) is an acute and highly contagious disease of young chickens caused by Birnavirus. Mortality of infected birds can be best prevented if injected with antibodies. The present study was an attempt to raise specific hyper-immune polyclonal antibodies against IBD virus in Pakistan. Commercial layers divided into four groups were injected with IBD vaccine subcutaneously according to four different treatment regimens. Eggs were collected daily and antibodies were purified from yolk with dextran sulphate. Titers of antibodies in serum and yolk were evaluated with enzyme linked immunosorbant assay and agar gel precipitation test. Antibody titers were significantly higher in yolk than serum. Eggs collected at 28 days post-vaccination had maximum antibody titers. Of treatment regimens, T3 was found to be most effective for hyperimmunization. Lyophilized antibodies stored at 4℃ did not lose their activity till the end of experiment. IBD virus infected birds were injected with purified antibodies which induced 92% recovery as compared to control birds. The study implicates that the purified antibodies may be useful as a therapeutic agent to cure IBD infected birds.
Collapse
Affiliation(s)
- Muhammad Wasif Malik
- Department of Biological Sciences, Quaid-i-Azam University, Islamabad P.O. Box 45320, Pakistan
| | | | | |
Collapse
|
20
|
Abstract
Although infections caused by the straminipilan pathogen Pythium insidiosum were described in 19th century, it has been only recently that its epidemiology, immunology, treatment and other important traits were extensively studied. These studies were of paramount importance to theorize about the ecological niche for this pathogen, its host-parasite relationships, the antigens used for diagnosis, and the management of the infection using immunotherapy. P. insidiosum triggers in the infected host a T helper 2 [Th2] subset with an inflammatory reaction composed mainly of eosinophils and mast cells. These cells degranulate around the hyphal elements of P. insidiosum where a Splendore-Hoeppli-like reaction develops. In horses this reaction is so intensive that firm concretions called 'kunkers' develop. These data indicated that this pathogen might have developed an evolutionary strategy to conceal important antigens from the host immune system. Immunotherapy, a treatment approach that relies on the injection of antigens of P. insidiosum from in vitro cultures, has been successfully used in humans and horses to manage this disease. A switch from a Th2 to Th1 response is postulated as the most likely explanation of the curative properties of this approach. This review provides details on the serological, immunological, and immunotherapeutic methodologies used to diagnose and treat the infections caused by this pathogen.
Collapse
Affiliation(s)
- Leonel Mendoza
- Medical Technology Program, Microbiology and Molecular Genetics, Michigan State University, East Lansing 48824-1031, USA.
| | | |
Collapse
|
21
|
Simou C, Thoday KL, Forsythe PJ, Hill PB. Adherence of Staphylococcus intermedius to corneocytes of healthy and atopic dogs: effect of pyoderma, pruritus score, treatment and gender. Vet Dermatol 2005; 16:385-91. [PMID: 16359305 DOI: 10.1111/j.1365-3164.2005.00484.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Staphylococcal pyoderma occurs commonly in atopic dogs. Some studies have suggested that adherence of staphylococci to corneocytes of atopic dogs and humans is higher than to corneocytes of healthy individuals. This hypothesis and possible differences resulting from the presence or absence of pyoderma, the severity of pruritus or the effect of treatment or gender, were studied. Adherent bacteria (Staphylococcus intermedius) were quantified by computerized image analysis on corneocytes collected from healthy or atopic dogs using double-sided adhesive tape. The adherence of S. intermedius to the corneocytes of atopic dogs was significantly greater than to those of healthy dogs (P=0.005). Furthermore, adherence was significantly greater in dogs with high levels of pruritus compared to those with low scores. No significant differences were found between atopic dogs with no history of pyoderma, atopic dogs with a history of pyoderma and atopic dogs with pyoderma at the time of sampling (P=0.068), suggesting that factors other than adherence are necessary for clinical pyoderma to develop. Treatment did not generally influence the adherence of S. intermedius to corneocytes of atopic dogs and there was no gender difference in adherence in either healthy or atopic dogs.
Collapse
Affiliation(s)
- Chrisi Simou
- The University of Edinburgh, Dermatology Unit, Division of Veterinary Clinical Studies, The Hospital for Small Animals, The Royal (Dick) School of Veterinary Studies, Easter Bush Veterinary Centre, Roslin, Midlothian, Scotland
| | | | | | | |
Collapse
|
22
|
Rodriguez-Lecompte JC, Kruth S, Gyorffy S, Wan YH, Gauldie J. Cell-based cancer gene therapy: breaking tolerance or inducing autoimmunity? Anim Health Res Rev 2005; 5:227-34. [PMID: 15984329 DOI: 10.1079/ahr200473] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
This review examines the mechanisms involved in anti-tumor immunity and how peptides present in many tumor types (tumor-associated antigens) are recognized by T cells from tumor-bearing cancer patients. Tumor-associated antigens are derived from proteins that are also expressed in normal cells. It is predicted that immune responses to such peptides will be compromised by self-tolerance or that stimulation of effective immune responses will be accompanied by autoimmunity. We also consider that the immunity induced against two autoantigens, which are highly conserved in vertebrates, involve qualitatively different mechanisms, such as the production of antibodies and cell-mediated immune responses. However, both pathways lead to tumor immunity and identical phenotypic manifestations of autoimmunity. Appropriate selection of the optimal tumor antigen is critical for the induction of an anti-tumor immune response. Thus, we stress that the methods for antigen presentation using dendritic cells play a critical role in the development of tumor vaccines, to break immune tolerance and induce a strong immune response against them. The viability and feasibility of expansion of canine dendritic cells from bone marrow and peripheral blood ex vivo for the treatment of spontaneous cancers in dogs is also discussed.
Collapse
|
23
|
Wellehan JFX, Farina LL, Keoughan CG, Lafortune M, Grooters AM, Mendoza L, Brown M, Terrell SP, Jacobson ER, Heard DJ. Pythiosis in a dromedary camel (Camelus dromedarius). J Zoo Wildl Med 2005; 35:564-8. [PMID: 15732604 DOI: 10.1638/03-098] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A 4.5-yr-old male dromedary camel (Camelus dromedarius) was evaluated for a mass on the right side of the face. A complete blood count and blood chemistry revealed anemia and hypoproteinemia. Radiographs did not reveal bony involvement. The mass was resected and Pythium insidiosum was cultured. The camel was treated with an experimental immunotherapeutic vaccine and with sodium iodide and ceftiofur. The camel began to lose weight postoperatively and died 6 mo later. At necropsy, the camel was found to have gastritis of the third compartment of the stomach with intralesional hyphae of this oomycete pathogen.
Collapse
Affiliation(s)
- James F X Wellehan
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida 32610, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Wang CY, Walfield AM. Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. Vaccine 2005; 23:2049-56. [PMID: 15755569 DOI: 10.1016/j.vaccine.2005.01.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
United Biomedical, Inc. (UBI) has developed a set of core technologies for the discovery and production of synthetic peptide-based immunotherapeutics and vaccines. These core technologies have led to products that stimulate functional site-directed antibody responses for therapeutic effects. UBI active immunotherapies can be used to modulate physiological processes effective for the control of cell entry by HIV virions, for control of prostate cancer and allergy, and for immunocastration in livestock leading to boar taint elimination and growth promotion in swine. The UBI technologies are also useful to stimulate site-directed antibodies against pathogenic agents such as foot-and-mouth disease virus. UBITh Immunotherapeutic peptides were developed as antigens to direct antibody responses against targeted epitopes on self-proteins and viral pathogens that are responsible for biological functions and pathogenicity. A collection of promiscuous UBITh T helper cell epitopes was used to impart these functionally antigenic peptides with immunogenicity. The T cell helper epitopes were covalently linked to the functional antigenic target sites by peptide synthesis, creating well-defined synthetic immunogens. Finally, vaccine formulations were selected appropriate for the delivery of peptide immunogens. Controlled production processes and the means to characterize the final product provide a framework for the GMP-compliant manufacture of UBITh immunotherapeutics and vaccines.
Collapse
Affiliation(s)
- Chang Yi Wang
- United Biomedical, Inc., 25 Davids Drive, Hauppauge, NY 11788, USA.
| | | |
Collapse
|
25
|
Abstract
Coccidiosis is a ubiquitous intestinal protozoan infection of poultry seriously impairing the growth and feed utilization of infected animals. Conventional disease control strategies rely heavily on chemoprophylaxis, which is a tremendous cost to the industry. Existing vaccines consist of live virulent or attenuated Eimeria strains with limited scope of protection against an ever-evolving and widespread pathogen. The continual emergence of drug-resistant strains of Eimeria, coupled with the increasing regulations and bans on the use of anticoccidial drugs in commercial poultry production, urges the need for novel approaches and alternative control strategies. Because of the complexity of the host immunity and the parasite life cycle, a comprehensive understanding of host-parasite interactions and protective immune mechanisms becomes necessary for successful prevention and control practices. Recent progress in functional genomics technology would facilitate the identification and characterization of host genes involved in immune responses as well as parasite genes and proteins that elicit protective host responses. This study reviews recent coccidiosis research and provides information on host immunity, immunomodulation, and the latest advances in live and recombinant vaccine development against coccidiosis. Such information will help magnify our understanding of host-parasite biology and mucosal immunology, and we hope it will lead to comprehensive designs of nutritional interventions and vaccination strategies for coccidiosis.
Collapse
Affiliation(s)
- Rami A Dalloul
- Animal Parasitic Diseases Laboratory, Animal and Natural Resources Institute, USDA-ARS, BARC-East, Building 1040, Beltsville, MD 20705, USA
| | | |
Collapse
|
26
|
Yasunaga S, Tsukui T, Masuda K, Ohno K, Tsujimoto H. CTLA-4 recombinant protein genetically fused to canine Fcepsilon receptor Ialpha enhances allergen specific lymphocyte responses in experimentally sensitized dogs. J Vet Med Sci 2004; 66:611-7. [PMID: 15240934 DOI: 10.1292/jvms.66.611] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Vaccination with a recombinant antigen fused to a targeting molecule is a potential strategy for inducing efficient immune responses. For the therapeutic purpose of allergic diseases in dogs, a DNA construct which expresses recombinant fusion protein with two functional domains, cytotoxic T lymphocyte antigen (CTLA-4) and Fcepsilon receptor Ialpha, was developed to bridge antigen-presenting cells and IgE-allergen complex. The recombinant fusion protein expressed by the DNA construct was demonstrated to retain the ability to bind monocytes in PBMC and dog IgE, respectively. Additionally, the recombinant protein induced enhancement of allergen-induced lymphoproliferation in experimentally sensitized dogs under conditions of suboptimal allergen stimulation. These results indicated that the DNA construct could enhance allergen-induced immune responses in vivo, implying its usefulness for perspective application in immunotherapy in dogs.
Collapse
Affiliation(s)
- Sho Yasunaga
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Japan
| | | | | | | | | |
Collapse
|
27
|
Falkinham JO, Gross WB, Pierson FW. Effect of different cell fractions of Mycobacterium avium and vaccination regimens on Mycobacterium avium infection. Scand J Immunol 2004; 59:478-84. [PMID: 15140058 DOI: 10.1111/j.0300-9475.2004.01419.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Because of the availability of uniform genetic stocks and the ability to modulate stress levels, chickens were investigated as a host for the development of an antimycobacterial vaccine. The imposition and the timing of stress significantly influenced the outcome of Mycobacterium avium infection in chickens. Simple, whole cell or lysate vaccines and combinations of vaccine preparations were identified that led to high levels of protection. In addition, short-term stress at the time of vaccination significantly increased the protective efficacy of M. avium vaccine preparations. Post-infection vaccination of M. avium-infected chickens was also shown to significantly reduce the number of lesions and colony counts.
Collapse
Affiliation(s)
- J O Falkinham
- Department of Biology, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA.
| | | | | |
Collapse
|
28
|
Abstract
Dendritic cells have been shown to be the main antigen-presenting cells in vitro and in vivo, playing a pivotal role in the induction of both tolerance and immunity. Dendritic cells from humans and mice have been extensively studied and dendritic cell-based vaccines have been shown to be effective in the prevention and treatment of infectious, allergic and neoplastic diseases. Studies of dendritic cells of domestic animal origin are becoming available and confirm a role for these cells in the pathogenesis of a variety of animal diseases, suggesting that dendritic cells could be used as adjuvants for prophylactic and therapeutic strategies in veterinary medicine.
Collapse
Affiliation(s)
- Y Vanloubbeeck
- Department of Veterinary Pathology, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA
| | | | | |
Collapse
|
29
|
Abstract
Canine transmissible venereal tumour (CTVT) is the only known naturally occurring tumour that can be transplanted as an allograft across major histocompatibility (MHC) barriers within the same species, and even to other members of the canine family, such as foxes, coyotes and wolves. The progression of this tumour is unique in that, it follows a predictable growth pattern. In natural and experimental cases, the growth pattern includes progressive growth phase, static phase and regression phase, and this is followed by transplantation immunity in immunocompetent adults, while metastasis occurs in puppies and immunosuppressed dogs. Because of the uniqueness of CTVT transmission and progression, experimental investigations of various aspects of the biology of CTVT have been used to provide clues to the immunobiology of both animal and human tumours. This review examines the current state of knowledge of the aspects of the cytogenetic origin, immunophenotype, immunobiology and immunotherapy of CTVT.
Collapse
Affiliation(s)
- S Mukaratirwa
- University of Zimbabwe, Faculty of Veterinary Science, Department of Paraclinical Studies, Mount Pleasant, Harare.
| | | |
Collapse
|
30
|
Abstract
A 4-year-old Labrador Retriever was referred for evaluation of 2 ulcerative nodular cutaneous lesions. One lesion was located on the medial aspect of the right carpus; the other was located on the medial aspect of the left tarsus. The dog had spent its entire life in the southeastern part of the United States and approximately half of its time outdoors with free access to a nearby lake. Histologic examination of full-thickness wedge biopsy specimens from both lesions revealed severe, multifocal, puruloeosinophilic to pyogranulomatous deep dermatitis with intralesional filamentous structures, fibroplasia, and neovascularization. Examination of sections stained with Gomori methenamine silver stain revealed a moderate number of wide, bulbous, irregularly septate, branching hyphae. Results of an immunodiffusion test and an ELISA for anti-Pythium insidiosum antibodies were positive. Amputation was eliminated as a treatment option because lesions involved 2 limbs. Long-term systemic antifungal treatment was also rejected because of the cost, lack of therapeutic effect in many cases, and potential for adverse effects. The dog was treated with 2 doses of an anti-P insidiosum vaccine administered 2 weeks apart. One month later, the lesions were nearly completely healed, and values obtained via the immunodiffusion test and ELISA had decreased. Results of the immunodiffusion test and ELISA were negative 1 year later, and the dog had not had any recurrences.
Collapse
Affiliation(s)
- Patrick Hensel
- Department of Small Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA
| | | | | | | | | |
Collapse
|
31
|
Davis EG, Rush BR, Blecha F. Increases in cytokine and antimicrobial peptide gene expression in horses by immunomodulation with Propionibacterium acnes. Vet Ther 2003; 4:5-11. [PMID: 12756631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
Immunomodulation with Propionibacterium acnes is used for prophylaxis of respiratory disease or in horses suffering from chronic pulmonary inflammation; however, the mechanism for this response is poorly understood. Semiquantitative reverse transcriptase-polymerase chain reaction assays were used to evaluate gene expression of interleukin (IL)-2, IL-10, interferon (IFN)-gamma, and NK-lysin in healthy horses treated with P. acnes. Findings in the study indicated that horses treated with a P. acnes-based immunomodulator exhibited increased IFN-gamma and NK-lysin gene expression in peripheral blood mononuclear cells. These results suggest that part of the immunostimulating properties of a P. acnes-based immunomodulator is derived from enhanced gene expression of the type-1 cytokine IFN-gamma and NK-lysin, an antimicrobial peptide.
Collapse
Affiliation(s)
- Elizabeth G Davis
- Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS, 66506, USA
| | | | | |
Collapse
|
32
|
Abstract
Recent advances in molecular biology, genomics, and immunology are revolutionizing our approach to managing infectious diseases of humans, livestock, and poultry. One of the most interesting additions to the armamentarium of research focusing on controlling infectious diseases has been a better understanding of how the host's innate immune system recognizes "danger" signals. Additionally, there has been recognition of the relationship between the innate and the specific arms of the immune system. For example, the recent discovery that CpG motifs can modulate immune responses has been used both as an adjuvant to enhance the responses to vaccines, as well as a direct immunostimulant to prevent infections. Using an Escherichia coli chicken model, we have been able to prevent cellulitis in chickens with CpG alone. Thus, CpG can be used immunoprophylactically to reduce infectious diseases. In addition, we will describe how CpG formulations with various antigens; recombinant proteins, peptides, and conventional vaccines can enhance immune responses to each of these different vaccine combinations. What is even more interesting is that CpG incorporation in vaccines can shift the immune response from a predominant T helper 2 (Th2)-like immune response generally induced by killed or subunit proteins to a much more balanced Th1-Th2 response. These immunomodulatory effects have significant implications for management of infectious diseases of all vertebrates.
Collapse
Affiliation(s)
- L A Babiuk
- Veterinary Infectious Disease Organization, 120 Veterinary Road, Saskatoon, SK, S7N 5E3 Canada.
| | | | | |
Collapse
|
33
|
Guarga JL, Moreno J, Lucientes J, Gracia MJ, Peribáñez MA, Castillo JA. Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet Immunol Immunopathol 2002; 88:13-20. [PMID: 12088640 DOI: 10.1016/s0165-2427(02)00128-9] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The efficacy of specific immunochemotherapy against Leishmania infantum infection in dog was studied. The effects on transmission of the disease, as well as the cellular and humoral immune response were examined. The treated animals showed a significant reduction in the infection rates that were detected in Phlebotomus perniciosus females fed on the dog. The humoral immune response, assayed with an indirect immunofluorescence antibody test (IFAT), did not show significant variations under the influence of the therapy. The characterisation of the peripheral blood mononuclear cells (PBMC) using flow cytometry indicated a significant increase in the proportion of T lymphocytes, especially of CD4/TcR(alpha)(beta)(+) and CD4/CD45RA(+) cells, without showing evidence for modifications in the other leukocyte subsets. Cellular lymphoproliferation studies indicated a lack of a specific response to soluble leishmanial antigen (SLA), but the non-specific lymphoproliferative capacity assayed with phytohemagglutinin (PHA) was maintained.
Collapse
Affiliation(s)
- Jose Luis Guarga
- Departamento de Patología Animal, Parasitología y Enfermedades Parasitarias, Facultad de Veterinaria, C/ Miguel Servet 177, 50013-Zaragoza, Spain
| | | | | | | | | | | |
Collapse
|
34
|
Park SJ, Yoshida N, Nishifuji K, Sekiguchi M, Momoi Y, Fukada T, Iwasaki T. Successful treatment of two dogs with allergic dermatitis by anti-allergic peptides (MS-antigen). J Vet Med Sci 2002; 64:63-5. [PMID: 11853148 DOI: 10.1292/jvms.64.63] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The effects of non-specific immunotherapy with anti-allergic peptides extracted from the urine of human allergic patients (MS-antigen), in two dogs with allergic dermatitis (AD) have been described. Clinically, severe pruritus accompanied by secondary bacterial pyoderma did not respond to conventional therapy with systemic antibiotics. The first clinical change appeared as a significant reduction in pruritus within 3 months, around the time of the 15th injection in both cases. The clinical condition was stabilized after 5 months, allowing the gradual withdrawal of concurrent therapies and an increase of injection intervals. The correlation between the results of intradermal skin tests before and after treatment and the improvement of clinical signs was not obvious.
Collapse
Affiliation(s)
- Song-Jung Park
- Gifu University, Veterinary Medical Teaching Hospital, Japan
| | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
The treatment of canine atopic dermatitis is multifaceted and consists of a combination of actions that include the use of allergen avoidance, anti-inflammatory agents, allergen-specific immunotherapy and antimicrobial drugs. The importance and order of these treatment steps vary from patient to patient. General recommendations for each of the therapeutic steps are highlighted in this paper. Specific details are covered in other papers of this issue.
Collapse
Affiliation(s)
- T Olivry
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 4700 Hillsborough Street, Raleigh, NC 27606, USA.
| | | |
Collapse
|
36
|
Abstract
Clinically ill feline leukemia virus (FeLV)-infected cats, treated with Staphylococcus protein A (SPA) or oral interferon alpha (IFN), or both, were compared with cats treated with saline (SAL). Nine cats received SPA/SAL, nine received SPA/IFN, 10 received SAL/IFN, and eight received SAL/SAL. Twelve cats survived and completed the 100-week therapy. Significantly more owners of cats treated with SPA/SAL thought their cat's health improved during treatment compared to owners of cats treated with SAL/SAL (P=0.05, pair-wise comparison) or SPA/IFN (P=0.05, pair-wise comparison). No significant differences in body weight, temperature, hematocrit, red blood cell counts, mean corpuscular hemoglobin concentration, reticulocyte counts, white blood cell or neutrophil numbers, lymphocyte concentrations, bone-marrow cytopathology, FeLV status, survival time, activity, or appetite scores were observed. No significant differences in the owners' subjective assessment of their cat's health following treatment with SAL/IFN, SPA/IFN, or SAL/SAL were seen. Therapy with SPA as a single agent results in the owners' subjective impression of improved health of their FeLV-infected cats.
Collapse
Affiliation(s)
- D L McCaw
- Department of Veterinary Medicine, College of Veterinary Medicine, University of Missouri, Columbia 65211, USA
| | | | | | | | | | | |
Collapse
|
37
|
Abstract
Serum samples from 40 atopic dogs and 20 healthy dogs were assayed for antinuclear antibodies (ANA) using a human epithelial cell line (HEp-2) and standard indirect immunofluorescent methods. Samples from the atopic dogs were grouped according to the presence (n = 28) or absence (n = 12) of facial lesions at any moment during the follow-up period. Positive ANA titres were found in 10 of the 40 atopic dogs analysed (25%) whereas samples from the control group were negative. Eight atopic dogs with facial lesions had a positive titre (28.57%) in contrast with atopic dogs without facial lesions where two positive samples (16.67%) were found; however, the differences were statistically not significant. Endpoint titres were low (1/40), only two samples yielded a 1/80 positive titre and one sample had a 1/320 titre, all of them from the facial lesions group. Response to immunotherapy was classified as positive only in four of the 10 ANA-positive patients (40%) compared with a response rate of 73% (22 of 30) in the ANA-negative atopic dogs. However, a Fisher's exact test showed a two-sided P-value of 0.122 which was considered statistically not significant. The overall response rate to immunotherapy for all atopic dogs was 65% (26 of 40). In conclusion, the prevalence of ANA is higher in atopic than in healthy dogs, especially if facial lesions are present. Although a clinically significant pathogenic contribution is not probable, this higher prevalence should be taken into account in the differential diagnosis of canine autoimmune dermatitis.
Collapse
Affiliation(s)
- P J Ginel
- Department of Animal Medicine and Surgery, Faculty of Veterinary Medicine, University of Córdoba, Córboda, Spain.
| | | |
Collapse
|
38
|
Rothstein E, Miller WH, Scott DW, Mohammed HO. Retrospective study of clinical observations on insect hypersensitivity and response to immunotherapy in allergic dogs. Can Vet J 2001; 42:361-3. [PMID: 11360857 PMCID: PMC1476501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
A retrospective study was conducted to evaluate the importance of insect hypersensitivity in atopic dogs in the northeastern United States. Fifty (63%) of 79 dogs tested with 7 insect allergens, other than flea, had positive reactions to one or more insects. No dog had positive reactions to insects only. Forty-four dogs underwent immunotherapy. Thirty-one had insect antigens in their prescription mixture and 13 had only conventional environmental allergens. There was no statistical difference in the response rate between the 2 groups. Thus, testing with insect allergens did not decrease the number of dogs with negative skin tests, and including insect allergens in immunotherapy mixtures did not improve the response rate.
Collapse
Affiliation(s)
- E Rothstein
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, USA
| | | | | | | |
Collapse
|
39
|
Abstract
Urticaria secondary to atopy may be a familial problem in some horses. Immunotherapy using a vaccine containing antigens selected on the basis of history and results of intradermal testing can be an effective method of managing atopy in horses; a response to therapy may be seen within 2 months.
Collapse
Affiliation(s)
- C A Rees
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, Texas A&M University, College Station 77843-4474, USA
| |
Collapse
|
40
|
Tomita GM, Wang Y, Paape MJ, Poultrel B, Rainard P. Influence of bispecific antibodies on the in vitro bactericidal activity of bovine neutrophils against Staphylococcus aureus. J Dairy Sci 2000; 83:2269-75. [PMID: 11049067 DOI: 10.3168/jds.s0022-0302(00)75111-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We conducted the following study to determine if bispecific antibodies enhance the bactericidal activity of bovine neutrophils. Bispecific antibodies were synthesized by chemically crosslinking bovine neutrophil monoclonal antibodies to Staphylococcus aureus 305 capsule polysaccharide monoclonal antibodies. The efficiency of chemically coupling monoclonal antibody monomers was approximately 50% for each bispecific antibody produced. Monoclonal antibodies against neutrophils enhanced the respiratory burst activity of neutrophils by 2.3- to 2.5-fold. To determine the influence of bispecific antibodies on neutrophil function, S. aureus 305 was preincubated with various concentrations of bispecific antibodies and neutrophils were then added to the opsonized bacteria at different bacteria to neutrophil ratios. The bactericidal activity of neutrophils was expressed as a percentage reduction in colony-forming units in test cultures compared with the number of colony-forming units in control test cultures that did not contain bispecific antibodies or neutrophils. The addition of bispecific antibodies to test cultures increased the bactericidal activity of neutrophils. A reduction in colony-forming units as a function of increasing the S. aureus 305 to neutrophils ratio was observed in both the absence and presence of bispecific antibodies. However, a greater reduction was observed in the presence of bispecific antibodies. Increasing concentrations of bispecific antibodies enhanced the bactericidal activity of neutrophils at a constant S. aureus 305 to neutrophil ratio of 1:500. The results indicate that bispecific antibodies that recognize both S. aureus 305 capsular polysaccharide and neutrophil antigens potentiate the bactericidal activity of neutrophils.
Collapse
Affiliation(s)
- G M Tomita
- Immunology and Disease Resistance Laboratory, ARS, USDA, Beltsville, MD 20705, USA.
| | | | | | | | | |
Collapse
|
41
|
Abstract
Cytokines are soluble proteins produced by nucleated cells throughout the body. They have wide ranging effects on cell growth and differentiation, mediating immune responses, haemopoiesis and tissue repair. Advances in recombinant DNA technology have led to a vast increase in knowledge of their biological properties and subsequently their use in human clinical trials. The use of human cytokines in feline medicine has been of limited success as the action of cytokines is often species restricted or their activity may be neutralized due to antibody formation. Recently, however, many feline cytokines have been cloned which raises the possibility of their future use in the management and prevention of feline disease. Ultimately, they may find widespread clinical uses including the treatment of cancer, cytopenias and viral infections and as vaccine adjuvants.
Collapse
Affiliation(s)
- S P Dunham
- Department of Veterinary Pathology, University of Glasgow, Bearsden Road, Glasgow G61 1QH, UK
| |
Collapse
|
42
|
Abstract
Surgery is the mainstay of treatment for equine tumors. Conservative treatment approaches which preserve function and appearance are increasingly used in clinical practice. This article covers the principles and applications of two conservative treatment modalities including local chemotherapy and immunotherapy. The therapeutic benefit of local chemotherapy is based on the direct drug delivery to tumor tissue, i.e., topical and intratumoral administration of cytotoxic agents in slow release formulation. This treatment modality is very effective for cutaneous tumors and does not result in any permanent damage to normal tissue. Immunotherapy produces antitumor effects primarily through the action of natural host defense mechanisms against tumor cells. Although the use of immunotherapy is still under investigation there are many examples of its successful application to treatment of selected equine tumors.
Collapse
Affiliation(s)
- A P Théon
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, USA
| |
Collapse
|
43
|
Abstract
The clinical records of 277 cases of canine atopy treated with specific allergen immunotherapy were reviewed. A good response was defined as control with immunotherapy either alone or with topical agents, a partial response as control with immunotherapy and other systemic agents, and a poor response as no perceived benefit and the immunotherapy discontinued. The mean follow-up period was 29.2 months (range 10 to 85 months). Ninety-one cases (33 per cent) were lost to follow-up or failed to comply with the therapeutic protocol. Of the remaining 186 cases, 40 (21.5 per cent) had a good response to immunotherapy, 74 (39.8 per cent) had a partial response, and 72 (38.7 per cent) had a poor response. Immunotherapy was therefore of long-term benefit in 114 dogs (61.3 per cent). No significant differences in response rates were associated with the breed or sex of the dog, or the age of onset of the disease, or with the type or number of allergens included in a vaccine. Dogs which had clinical signs for more than 61 months before immunotherapy had a significantly poorer response rate (23.5 per cent, P < 0.05). In-house cases had a significantly better response rate (95.2 per cent, P < 0.05) than externally managed cases.
Collapse
Affiliation(s)
- T J Nuttall
- Royal (Dick) School of Veterinary Studies, Summerhall, Edinburgh
| | | | | | | | | | | |
Collapse
|
44
|
Proceedings of the First International Symposium on Cytokines and the Type I, Type II Paradigm. Cairns, Australia, Oct. 25-30, 1996. Vet Immunol Immunopathol 1998; 63:1-207. [PMID: 9656434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
45
|
Abstract
Pharmacologic manipulation of pulmonary immunity plays an important role in primary and adjunct therapy for equine respiratory disease. Frequent exposure to respiratory viral pathogens, strenuous exercise, long distance transport, and inhalation of harmful substances destroy various aspects of the pulmonary defense system and predispose performance horses to development of infectious and noninfectious respiratory disease. Pulmonary immunity may be bolstered by nonspecific immunostimulants to combat primary or secondary immunodeficiency. State of the art technology improves active and passive-specific immunity for prevention of common infectious respiratory diseases in horses. Immuno-suppressive therapy can attenuate hyperreactive pulmonary immune responses in horses with allergic airway disease.
Collapse
Affiliation(s)
- B R Rush
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, USA
| |
Collapse
|
46
|
Abstract
Since the first report of BRSV in the 1970s, the understanding of this agent and its respective disease has increased dramatically. Current evidence supports a major role for this virus in bovine respiratory disease. Advances in diagnostics have increased the ability to demonstrate this virus in field outbreaks of respiratory disease. The clinical signs and pathologic features have been well described, and vaccines are available to aid in prevention and control. Still, many questions remain to be answered with respect to BRSV. It appears there may be antigenic subgroups of BRSV, but the epidemiologic significance and relevance to immunization of this remains unknown. The question of differences in virulence among isolates of this virus has yet to be addressed. From an epidemiologic standpoint, the means by which BRSV perpetuates in the cattle population has yet to be elucidated. Although progress has been made in understanding the pathogenesis and immune response to BRSV, the mechanism of disease production and immune protection is incomplete. Lastly, efficacy testing of existing vaccines need to continue, as well as the development of new vaccines and new approaches to vaccination.
Collapse
Affiliation(s)
- J C Baker
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, USA
| | | | | |
Collapse
|
47
|
Abstract
Immunomodulation is now possible in veterinary medicine with the licensure of a number of biological products by the United States Department of Agriculture for veterinary use. These products activate primarily macrophages, induce the production of cytokines, and have various effects on the activity and proliferation of B and T lymphocytes. Those products most commonly used are inactivated whole bacteria of Propionibacterium acnes, cell wall fractions of nonpathogenic Mycobacterium spp, and the lysate derived from lysis of Staphylococcus aureus by a bacterial phage. All products have been licensed for use against specific diseases, but the literature includes studies for off-label usage. These immunomodulators are considered to be nonspecific stimulators of the immune system and may affect both humoral and cellular functions of immunity.
Collapse
|
48
|
Abstract
Vaccine adjuvants provide enhanced immune responses to a variety of antigens. Unlike human vaccines that are limited to aluminum-based adjuvants, veterinary vaccines may contain a large number of substances either alone or in combination that act as vaccine adjuvants. Although the use of adjuvants in veterinary vaccines enhances the immunogenicity of vaccines, they have been responsible for a number of side effects. This article explores the rationale of currently used vaccine adjuvants and some of the adverse events associated with their use in veterinary medicine.
Collapse
Affiliation(s)
- D W Macy
- Department of Clinical Sciences, Colorado State University, College of Veterinary Medicine and Biomedical Sciences, Fort Collins 80523, USA
| |
Collapse
|
49
|
Abstract
The application of gene therapy to the treatment of human and veterinary diseases offers an innovative addition to the clinician's treatment options. Gene therapy can potentially be used to (1) replace defective or missing genes, (2) treat cancer, and (3) deliver drugs. The focus of this paper is the use of gene therapy in the treatment of cancer. To be effective, genes must be delivered to target cells which can then serve as the factory to produce the gene product. Delivery systems include retroviral vectors, adenoviral vectors, and direct introduction of plasmid DNA into cells. In the case of cancer immunotherapy, introduced genes produce products that enhance tumor immunosurveillance and tumor cell killing by immune mechanisms.
Collapse
Affiliation(s)
- R E Elmslie
- Veterinary Cancer Specialists, Denver, CO 80210-5811, USA
| | | |
Collapse
|
50
|
Ferreira Neto JS, Vasconcellos SA, Ito FH, Moretti AS, Camargo CA, Sakamoto SM, Marangon S, Turilli C, Martini M. Leptospira interrogans serovar icterohaemorrhagiae seropositivity and the reproductive performance of sows. Prev Vet Med 1997; 31:87-93. [PMID: 9234428 DOI: 10.1016/s0167-5877(96)01120-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The reproductive performance of 28 sows seropositive to Leptospira interrogans serovar icterohaemorrhagiae was compared with that of 87 Leptospira sp. seronegative dams belonging to the same herd. Sows were sampled during 1988 to 1993. During this period the herd was not submitted to any kind of intervention (antibiotic therapy, immunoprophylaxis or rodent control). Relative risks (RR) of return to heat, mummified fetuses, stillbirth, and weak newborn piglets for infected sows were assessed and the differences in means of total piglets born per litter, piglets born alive, piglets effectively housed, weaned piglets, stillbirths, mummified fetuses, weak newborn piglets, weight at birth of the piglets effectively housed, weight at 21 days of life and weight at weaning were evaluated. Seropositive dams had a greater risk of having weak newborn piglets (RR = 1.67, 1.02 < or = CI 95% < or = 2.72) and also of having more weak newborn piglets per litter (P = 0.01). Other variables examined were not different (P > 0.05).
Collapse
Affiliation(s)
- J S Ferreira Neto
- Departamento de Medicina Veterinária Preventiva e Saúde Animal, Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, Brazil
| | | | | | | | | | | | | | | | | |
Collapse
|